Progyny, Inc.
NASDAQ:PGNYMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $2.66B
- Beta
- 1.04
- P/E (TTM)
- 31.4
- EPS (TTM)
- $0.84
Volume 0.88M
Average 1.49M
PGNY Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Progyny, Inc.NASDAQ: PGNY
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures grows, but more slowly than its trailing trend
Q2 FY2026 capital expenditures of $12.57M (cash outflow) rose 138.5% year over year, behind the +147.5% change in trailing-twelve-month capital expenditures. Sequentially, it rose 98.0% from the prior quarter. Over 3 fiscal years it compounded at +78.4% a year.
Context
- Capital expenditures amounted to 1.4% of revenue in FY2025, up 1.0 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +138.5% toward the trailing-twelve-month pace of +147.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (18.41M) USD
- Year-over-year change
- -240.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (18.41M) | -240.6% |
| FY2024 | 2024-12-31 | (5.41M) | -48.3% |
| FY2023 | 2023-12-31 | (3.64M) | -12.4% |
| FY2022 | 2022-12-31 | (3.24M) | -52.2% |
| FY2021 | 2021-12-31 | (2.13M) | — |
Capital Expenditures vs competitors
How PGNY compares with its peers on the latest reported figures
- PGNY's LTM Jun 2026 capital expenditures of $29.21M is the largest of the 3 companies compared; the peer median is $9.8M.
- Its year-over-year change of +147.5% is the highest of 3, against a peer median of -53.6%.
- Capital expenditures amounts to 2.2% of revenue for PGNY, versus a peer median of 0.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $29.21M | +147.5% | +78.4% | 2.2% | |
| LTM Jul 2026 | $18.51M | -32.2% | -74.5% | 1.4% | |
| LTM Mar 2026 | $1.09M | -74.9% | -21.4% | 0.4% | |
| Peer median (excluding PGNY) | $9.8M | -53.6% | -48.0% | 0.9% | |
Competitors are the stored peer set for PGNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 65.77M | 30.36M | 62.04M | 54.34M | 58.52M |
| Depreciation & Amortization | 1.3M | 1.6M | 2.28M | 3.18M | 4.95M |
| Deferred Income Tax | (33.3M) | (6.62M) | 3.75M | (10.46M) | (8.12M) |
| Stock-Based Compensation | 33.71M | 100.75M | 122.61M | 128.13M | 131.87M |
| Change in Working Capital | (51.26M) | (59.49M) | (17.42M) | (11.78M) | 2.8M |
| Accounts Receivables | (68.68M) | (119.3M) | (21.74M) | (9.87M) | (5.12M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 17.84M | 47.69M | 16.24M | (30.27M) | 28.75M |
| Other Working Capital | (421K) | 12.12M | (11.92M) | 28.37M | (20.84M) |
| Other Non-Cash Items | 9.82M | 13.79M | 15.56M | 15.7M | 20.17M |
| Operating Cash Flow | 26.04M | 80.4M | 188.81M | 179.11M | 210.19M |
| Capital Expenditures | (2.13M) | (3.24M) | (3.64M) | (5.41M) | (18.41M) |
| Acquisitions (Net) | 0 | 0 | 0 | (5.3M) | (9.34M) |
| Purchases of Investments | (111.48M) | (163.33M) | (429.69M) | (170.34M) | (354.96M) |
| Sales of Investments | 122.37M | 122.71M | 232.81M | 376.84M | 223.7M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 8.77M | (43.87M) | (200.53M) | 195.79M | (159.01M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.27M | 4.23M | 6.13M | 2.4M | 1.23M |
| Common Stock Repurchased | 0 | 0 | 0 | (300.28M) | (81.66M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (17.97M) | (12.09M) | (17.2M) | (12M) | (18.94M) |
| Financing Cash Flow | (13.7M) | (7.86M) | (11.07M) | (309.88M) | (99.36M) |
| Effect of Forex Changes | 0 | 0 | 1K | 1K | 62K |
| Net Change in Cash | 21.11M | 28.67M | (22.78M) | 65.02M | (48.12M) |
| Free Cash Flow | 23.91M | 77.15M | 185.17M | 173.7M | 191.78M |
Progyny, Inc.
NASDAQ:PGNY
Intrinsic Alpha fair value
Locked
Current Price
$36.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.